FDA approves first generic naloxone nasal spray to treat opioid overdose
The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose. The agency is also planning new steps to prioritize the review of additional generic drug applications for products intended to treat opioid overdose, along with the previously announced action to help facilitate an over-the-counter naloxone product. (Source: World Pharma News)
Source: World Pharma News - April 19, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Roche reports a strong start in 2019 and raises the outlook for the full-year
In the first three months of 2019, Group sales rose 8% to CHF 14.8 billion. Sales in the Pharmaceuticals Division increased 10% to CHF 11.9 billion. Key growth drivers were the multiple sclerosis medicine Ocrevus and cancer medicines Perjeta and Tecentriq as well as the new haemophilia medicine Hemlibra. (Source: World Pharma News)
Source: World Pharma News - April 18, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

World Hemophilia Day: Sanofi Genzyme donation impacts patients across the globe
On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of unmet needs for patients. Hemophilia is a rare, genetic bleeding disorder in which the ability of a person's blood to clot is impaired, which can lead to bleeding episodes that can cause pain, irreversible joint damage, and life-threatening hemorrhages. (Source: World Pharma News)
Source: World Pharma News - April 17, 2019 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Cannabidiol could help deliver medications to the brain
Cannabidiol (CBD), a non-psychoactive compound in cannabis, is being touted as beneficial for many health conditions, ranging from anxiety to epilepsy. Although much more research is needed to verify these claims, scientists have now shown that CBD could have a different use as a "Trojan horse": helping slip medications across the blood-brain barrier (BBB) and into mouse brains. (Source: World Pharma News)
Source: World Pharma News - April 17, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Independent large real-world study comparing NOACs in AF-patients
The results from an independent retrospective comparative study, published in January 2019 in the American Journal of Medicine, showed that dabigatran was associated with a more favourable benefit-harm profile than both warfarin and rivaroxaban. (Source: World Pharma News)
Source: World Pharma News - April 16, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

EVENITY ™ (romosozumab-aqqg) now available in the United States for the treatment of osteoporosis in postmenopausal women at high risk for fracture
Amgen (NASDAQ: AMGN) announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture. (Source: World Pharma News)
Source: World Pharma News - April 16, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

High-dose vitamin D shows benefit in patients with advanced colorectal cancer
Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease, say scientists from Dana-Farber Cancer Institute. Prompted by the "very encouraging" results of the SUNSHINE clinical trial, the potential benefits of vitamin D supplementation in metastatic colorectal cancer will (Source: World Pharma News)
Source: World Pharma News - April 15, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first targeted therapy for metastatic bladder cancer
The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. (Source: World Pharma News)
Source: World Pharma News - April 15, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Bristol-Myers Squibb shareholders approve Celgene acquisition
Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company's pending merger with Celgene Corporation (NASDAQ:CELG) at the Special Meeting of Stockholders. (Source: World Pharma News)
Source: World Pharma News - April 12, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

FDA approves EVENITY ™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture. (Source: World Pharma News)
Source: World Pharma News - April 12, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

One-third of cancer patients use complementary and alternative medicine
A stunning one-third of people with a cancer diagnosis use complementary and alternative medicines such as meditation, yoga, acupuncture, herbal medicine, and supplements. UT Southwestern Medical Center's Dr. Nina Sanford made the discovery that's now drawing renewed attention to habits she said cancer patients must disclose during treatment. Dr. Sanford is an Assistant Professor of Radiation Oncology who specializes in and treats cancers of the gastrointestinal tract. (Source: World Pharma News)
Source: World Pharma News - April 11, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture
The U.S. Food and Drug Administration approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies. (Source: World Pharma News)
Source: World Pharma News - April 10, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depositary Receipts), with each holder receiving 1 Alcon share for every 5 Novartis shares or ADRs held on April 8, 2019, at the close of business. (Source: World Pharma News)
Source: World Pharma News - April 9, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
Sanofi and Alnylam have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran, as previously announced, will continue unchanged. (Source: World Pharma News)
Source: World Pharma News - April 8, 2019 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Immune cells fighting blood cancer visualized for the first time
When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) represent a promising immunotherapy strategy, developed with the aim of tackling tumors head-on. But the occurrence of relapse in some patients remains a challenge. (Source: World Pharma News)
Source: World Pharma News - April 8, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Boehringer Ingelheim enhances oncology R & D with novel MacroDel delivery technology via acquisition of ICD Therapeutics
Boehringer Ingelheim announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD's innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will employ this platform for the development of novel therapeutics in collaboration with nanoPET Pharma GmbH, a former shareholder of ICD Therapeutics. (Source: World Pharma News)
Source: World Pharma News - April 5, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Compound that kills drug-resistant fungi is isolated from ant microbiota
Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a major public health problem worldwide. A study published recently in the journal Nature Communications suggests that the solution may come from the tiny bodies of insects, or more accurately, from the microbiota that they host. (Source: World Pharma News)
Source: World Pharma News - April 4, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA expands approved use of metastatic breast cancer treatment to include male patients
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. (Source: World Pharma News)
Source: World Pharma News - April 4, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre
Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. (Source: World Pharma News)
Source: World Pharma News - April 3, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

First bacterial genome created entirely with a computer
All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United States. As of today, the database has an additional entry: Caulobacter ethensis-2.0. It is the world's first fully computer-generated genome of a living organism, developed by scientists at ETH Zurich. (Source: World Pharma News)
Source: World Pharma News - April 3, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new medicine selumetinib. (Source: World Pharma News)
Source: World Pharma News - April 2, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Liver, colon cancer cells thwarted by compounds derived from hops
The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as well, new research at Oregon State University shows. Unlike the primary compound, xanthohumol, known as XN, the derivatives don't metabolize into phytoestrogens. (Source: World Pharma News)
Source: World Pharma News - April 2, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
AveXis, a Novartis company, today announced it signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont, Colorado, further expanding AveXis' production capacity as it prepares to launch Zolgensma® (onasemnogene abeparvovec-xioi[1]) an investigational gene therapy awaiting global regulatory approvals for the treatment of spinal muscular atrophy (SMA) Type 1 and for future gene therapy treatments in development. (Source: World Pharma News)
Source: World Pharma News - April 1, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Sugar could be sweet solution to respiratory disease
Restriction or inhalation of common sugar could one day treat a range of respiratory diseases, according to new research led by University of Manchester biologists. The study in mice reveals how the ability of cells to use glucose helps to regulate the immune system during lung inflammation. (Source: World Pharma News)
Source: World Pharma News - April 1, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Last call for registrations to Pre-Filled Syringes East Coast conference
8 - 9 April 2019, Boston, USA. SMi's global portfolio of events on Pre-Filled Syringes secured an audience of over 300 senior drug delivery and medical device experts over the last year. Next week will be held the 6th annual Pre-Filled Syringes East Coast conference and exhibition where industry leaders from pharmaceutical, biotech and device manufacturing, meet to get updates on medical devices advances, parenteral drug delivery, share experiences and network. (Source: World Pharma News)
Source: World Pharma News - March 29, 2019 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Clinical trial finds therapy to be well-tolerated in patients with aggressive brain tumour
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. The trial used a treatment combination of ADI-PEG20, pemetrexed and cisplatin, which showed encouraging efficacy in patients with recurrent high-grade gliomas (HGGs), a disease for which little progress has been made over the last few decades. (Source: World Pharma News)
Source: World Pharma News - March 29, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves treatment for patients with a type of inflammatory arthritis
The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA. (Source: World Pharma News)
Source: World Pharma News - March 28, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Researchers target metastasis in fight against cancer
An experimental combination drug therapy attacking the DNA integrity of cancer cells is showing promise for a possible new cancer therapy in the future. Scientists at the University of Alberta used two drugs together to enhance DNA damage to human breast cancer cells in mice and reduce their capacity to repair themselves. By doing so, the researchers were able to dramatically shrink tumours and prevent metastasis in the mice. (Source: World Pharma News)
Source: World Pharma News - March 28, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis receives FDA approval for Mayzent ® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis (SPMS) with active disease, relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS)*. (Source: World Pharma News)
Source: World Pharma News - March 27, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Forxiga approved in Japan for type-1 diabetes
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). The approval is based on data from the Phase III DEPICT clinical programme and a dedicated trial in Japanese patients (D1695C00001). (Source: World Pharma News)
Source: World Pharma News - March 27, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

BridgIT, a new tool for orphan and novel enzyme reactions
Effective protein engineering can give us control over the generated products inside a cell. However, for many of the biochemical reactions responsible for these products, we don't we don't know the specific protein- or enzyme-producing gene responsible. These reactions are called "orphan" and have become a big problem for protein engineers. (Source: World Pharma News)
Source: World Pharma News - March 26, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibrotic medicine is already approved in more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis (IPF). (Source: World Pharma News)
Source: World Pharma News - March 26, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

New technique shows promise for heart muscle regeneration
Researchers at Duke-NUS Medical School, Singapore, have developed an approach to regenerate heart muscle using stem cells. Their method for priming stem cells to become heart tissues could potentially enable heart regeneration stem cell therapies, according to their study published in the journal Cell Reports. (Source: World Pharma News)
Source: World Pharma News - March 25, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bayer reaches settlement to resolve Xarelto ™ litigation
More than five years after the Xarelto™ litigation began, and with Bayer and Janssen Pharmaceuticals prevailing in all six cases that went to trial, the companies have reached an agreement in principle to settle in the amount of 775 million U.S. dollars. (Source: World Pharma News)
Source: World Pharma News - March 25, 2019 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Data sharing by popular health apps is 'routine,' research finds
Mobile health apps are a booming market targeted at both patients and health professionals. Medicines-related apps help patients track their prescriptions and remember to take their pills. They also provide drug information to help clinicians prescribe and administer medications. (Source: World Pharma News)
Source: World Pharma News - March 22, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
PARIS & Vivet Therapeutics ("Vivet"), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. (Source: World Pharma News)
Source: World Pharma News - March 21, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Bayer is taking collaboration with health care start-ups to the next level
As a pioneer when it comes to collaborating with digital health start-ups, Bayer is now taking the next step. Instead of one-off startup programs, it is now focusing on collaborating in specific digital health focus areas, e.g. digital therapeutics, AI for drug discovery, and patient engagement platforms to name a few. To do this, Bayer is combining the G4A programs and concentrating on longer-term collaborations and investments. (Source: World Pharma News)
Source: World Pharma News - March 21, 2019 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: World Pharma News)
Source: World Pharma News - March 20, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Algae could prevent limb amputation
A new algae-based treatment could reduce the need for amputation in people with critical limb ischaemia, according to new research funded by the British Heart Foundation, published today in the journal npj Regenerative Medicine. Researchers at St Thomas' Hospital and King's College London have made small capsules from brown algae which hold macrophages, a type of white blood cell. (Source: World Pharma News)
Source: World Pharma News - March 20, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Merck to collaborate with GenScript to accelerate cell and gene therapy industrialization in China
Merck, a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing. (Source: World Pharma News)
Source: World Pharma News - March 19, 2019 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Go for a run or eat chocolate: A choice dictated by the cannabinoid receptors
Physical inactivity is a common factor in lifestyle diseases - and one that is often linked to the excessive consumption of fatty and/or sugary foods. The opposite scenario of excessive physical activity at the expense of caloric intake can also be harmful, as cases of anorexia nervosa illustrate. These data therefore point to the crucial need to research the neurobiological processes that control the respective motivations for exercise and food intake. (Source: World Pharma News)
Source: World Pharma News - March 19, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs. Saracatinib is an inhibitor of src kinase which regulates broad cell functions including cell growth and cell differentiation. (Source: World Pharma News)
Source: World Pharma News - March 18, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Diabetes drug effective against heart failure in wide spectrum of patients
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction, a measure of the heart's pumping ability indicative of poor heart functioning, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (Source: World Pharma News)
Source: World Pharma News - March 18, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction. (Source: World Pharma News)
Source: World Pharma News - March 15, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Merck announces collaboration with Iktos for generative artificial intelligence (AI) technology
Merck, a leading science and technology company, today announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds. (Source: World Pharma News)
Source: World Pharma News - March 14, 2019 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Green tea cuts obesity, health risks in mice
Green tea cut obesity and a number of inflammatory biomarkers linked with poor health in a new study. Mice fed a diet of 2 percent green tea extract fared far better than those that ate a diet without it, a finding that has prompted an upcoming study of green tea's potential benefits in people at high risk of diabetes and heart disease. (Source: World Pharma News)
Source: World Pharma News - March 14, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Exclusive speaker interview with SCHOTT Pharmaceutical Systems released for Pre-Filled Syringes East Coast 2019
8 - 9 April 2019, Boston, USA. The 6th Annual Pre-Filled Syringes East Coast conference is returning to Boston, USA. The two-day event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry. (Source: World Pharma News)
Source: World Pharma News - March 13, 2019 Category: Pharmaceuticals Tags: Featured Events Source Type: news

New cholesterol-lowering drug could help patients unable to take statins
A new class of oral cholesterol-lowering drug could help patients unable to take statins due to side effects. The findings come from the largest study to date to test the effectiveness and safety of bempedoic acid, an oral medication - yet to be approved in Europe - which inhibits the body's ability to create the building blocks of cholesterol. (Source: World Pharma News)
Source: World Pharma News - March 13, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

When a cell's 'fingerprint' can be a weapon against cancer
A research team led by Nuno Barbosa Morais, group leader at Instituto de Medicina Molecular João Lobo Antunes (iMM) in Lisbon, computationally analysed the expression of marker genes that are associated with a "fingerprint" of cancer cells in thousands of tumors and revealed its therapeutic potential in the fight against cancer. The study published in the scientific journal PLoS Computational Biology shows (Source: World Pharma News)
Source: World Pharma News - March 12, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves a new generic valsartan
Today, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan). Valsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart failure. The FDA prioritized the review of this drug application to help relieve the recent shortage of this critical medicine (Source: World Pharma News)
Source: World Pharma News - March 12, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news